Work

Abstract PS5-12-22: Trofuse-012: a phase 3, randomized study of adjuvant sacituzumab tirumotecan plus pembrolizumab vs treatment of physician’s choice in participants with triple-negative breast cancer who received neoadjuvant therapy and did not achieve a pathological complete response at surgery

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps5-12-22

Authors: H. L. McArthur, R. Dent, R. Hui, Y. Park, P. Schmid, J. Wei, J. A. Mejia, W. Pan, J. Cortés

Institutions: The University of Texas Southwestern Medical Center, National University of Singapore, Duke-NUS Medical School, National Cancer Centre Singapore, The University of Sydney, Westmead Hospital, University of Hong Kong, Samsung Medical Center, Sungkyunkwan University, Queen Mary University of London, Barts Cancer Institute, Merck & Co., Inc., Rahway, NJ, USA (United States), MedSIR (Spain), Universidad Europea de Madrid

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129758307

Cites:

Cited by:

Related to: